[go: up one dir, main page]

WO2022065983A3 - Coronavirus infection preventing or treating composition comprising gynostemma pentaphyllum extract - Google Patents

Coronavirus infection preventing or treating composition comprising gynostemma pentaphyllum extract Download PDF

Info

Publication number
WO2022065983A3
WO2022065983A3 PCT/KR2021/013240 KR2021013240W WO2022065983A3 WO 2022065983 A3 WO2022065983 A3 WO 2022065983A3 KR 2021013240 W KR2021013240 W KR 2021013240W WO 2022065983 A3 WO2022065983 A3 WO 2022065983A3
Authority
WO
WIPO (PCT)
Prior art keywords
coronavirus
gynostemma pentaphyllum
preventing
pentaphyllum extract
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2021/013240
Other languages
French (fr)
Korean (ko)
Other versions
WO2022065983A2 (en
Inventor
마진열
조원경
김기옥
전형식
도기식
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JEJU TECHNOPARK
Nanum Pharm Co Ltd
Korea Institute of Oriental Medicine KIOM
Original Assignee
JEJU TECHNOPARK
Nanum Pharm Co Ltd
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JEJU TECHNOPARK, Nanum Pharm Co Ltd, Korea Institute of Oriental Medicine KIOM filed Critical JEJU TECHNOPARK
Priority claimed from KR1020210127809A external-priority patent/KR102748815B1/en
Publication of WO2022065983A2 publication Critical patent/WO2022065983A2/en
Publication of WO2022065983A3 publication Critical patent/WO2022065983A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/424—Gynostemma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to the antiviral use against coronavirus, comprising a Gynostemma pentaphyllum extract or a fraction thereof and, more particularly, to: an antiviral pharmaceutical composition against coronavirus, comprising a Gynostemma pentaphyllum extract or a fraction thereof; a pharmaceutical composition for preventing or treating coronavirus infectious diseases; a method for preventing or treating coronavirus infectious diseases by means of the pharmaceutical composition; a functional health food composition for preventing or relieving coronavirus infectious diseases, comprising a Gynostemma pentaphyllum extract or a fraction thereof; and a feed composition for preventing or relieving coronavirus infectious diseases, comprising a Gynostemma pentaphyllum extract or a fraction thereof. The Gynostemma pentaphyllum extract of the present invention shows an inhibitory effect against an infection of coronavirus such as MERS-coronavirus, SARS-coronavirus and SARS-coronavirus-2, and thus can be used for developing an antiviral agent for preventing or treating the viral diseases.
PCT/KR2021/013240 2020-09-28 2021-09-28 Coronavirus infection preventing or treating composition comprising gynostemma pentaphyllum extract Ceased WO2022065983A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2020-0126189 2020-09-28
KR20200126189 2020-09-28
KR1020210127809A KR102748815B1 (en) 2020-09-28 2021-09-28 Composition for preventing or treating corona virus comprising HGynostemma pentaphyllum extracts
KR10-2021-0127809 2021-09-28

Publications (2)

Publication Number Publication Date
WO2022065983A2 WO2022065983A2 (en) 2022-03-31
WO2022065983A3 true WO2022065983A3 (en) 2022-05-19

Family

ID=80846760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/013240 Ceased WO2022065983A2 (en) 2020-09-28 2021-09-28 Coronavirus infection preventing or treating composition comprising gynostemma pentaphyllum extract

Country Status (1)

Country Link
WO (1) WO2022065983A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4216013B2 (en) * 2002-07-26 2009-01-28 株式会社ロッテ Anti-influenza virus agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4216013B2 (en) * 2002-07-26 2009-01-28 株式会社ロッテ Anti-influenza virus agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EL OKOYE, GO EZEIFEKA , CO ESIMONE: "The antiviral activity of 'Gynostemma pentaphyllum' against yellow fever virus", JOURNAL OF HERBAL MEDICINE, vol. 24, no. 4, 1 January 2012 (2012-01-01), pages 128 - 134, XP055929805, ISSN: 2200-3886 *
OKOYE E L: "In vitro evaluation of the antiviral activity of extract of gynostemma pentaphyllum against poliomyelitis virus", INTERNATIONAL JOURNAL OF AGRICULTURE AND BIOSCIENCES, vol. 2, no. 2, 1 January 2013 (2013-01-01), Nigeria, pages 64 - 67, XP009536672, ISSN: 2305-6622 *
OKOYE, E. L,, NWORU, C. S., EZEIFEKA, G. O., ESIMONE, C. O: "Inhibition of HIV-1 lentiviral particles infectivity by Gynostemma pentaphyllum extracts in a viral vector-based assay", AFRICAN JOURNAL OF BIOTECHNOLOGY, vol. 11, no. 7, 24 January 2012 (2012-01-24), pages 1782 - 1788, XP055929812, DOI: 10.5897/AJB11.2841 *
UNCLE CHADEE: "Stay away from COVID-19 with jiaogulan tea", 10 August 2020 (2020-08-10), pages 1 - 6, XP055929799, Retrieved from the Internet <URL:https://webcache.googleusercontent.com/search?q=cache:s1xrqENt_mEJ:https://www.northlandtea.com/blogs/northlandtea-blog/stay-away-from-covid-19-with-jiaogulan-tea+&cd=2&hl=ko&ct=clnk&gl=kr> *

Also Published As

Publication number Publication date
WO2022065983A2 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
ZA202500439B (en) Therapeutic compounds for hiv virus infection
MY209319A (en) Compounds useful to treat influenza virus infections
PH12021550813A1 (en) Inhibitors of human immunodeficiency virus replication
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2019086141A8 (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
CA2998646C (en) 4&#39;-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12017501958B1 (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2020250209A3 (en) Lactoferrin for oral use with antiviral action
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2022009871A (en) Tetracyclic compounds for treating hiv infection.
MX2021004182A (en) Macrocyclic flu endonuclease inhibitors.
MX2018011788A (en) Substituted indoline derivatives as dengue viral replication inhibitors.
MX2021007069A (en) 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM.
MX2021010145A (en) Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases.
WO2022129097A3 (en) Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
PH12021551408A1 (en) Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
MX2021014301A (en) Other heteroaromatic compounds having activity against rsv.
WO2022065983A3 (en) Coronavirus infection preventing or treating composition comprising gynostemma pentaphyllum extract
MX2020011200A (en) Heteroaromatic compounds having activity against rsv.
WO2022065970A3 (en) Composition comprising natural product mixed extract for prevention or treatment of coronavirus infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21873011

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21873011

Country of ref document: EP

Kind code of ref document: A2